A South Korea lupus treatment budget starts by separating coverage categories
Systemic lupus erythematosus, usually shortened to SLE, is a chronic autoimmune disease that can affect the skin, joints, blood, kidneys, nervous system, lungs, heart, and other organs.
Two people with the same broad diagnosis can have very different disease activity, organ involvement, medicines, monitoring schedules, hospital use, and costs.
A single national average for a month of lupus care would therefore hide the decisions that matter most for an individual budget.
Standard-care spending
Enter the covered and non-covered costs that appear on your own hospital estimate or recent receipts, including medicines, visits, and monitoring outside belimumab.
Belimumab infusion spending
Estimate a 10 mg/kg intravenous dose, the lowest-price integer combination of 120 mg and 400 mg vials, and the loading plus every-28-day schedule.
Korean coverage rules
Keep HIRA reimbursement, the M32.1 and V136 special-case registration, ordinary copays, outside-criteria drug cost, and the annual ceiling in separate buckets.
This is a planning guide, not medical advice, a diagnosis, a prescription, or an insurer decision.
Medicine selection, dose adjustment, pregnancy planning, infection precautions, central nervous system disease, and lupus nephritis require an individual specialist assessment.
The shared English estimator above is a compact budget scenario for Korea-specific medical costs.
The detailed Korean calculator separately models the vial mix, exact infusion dates, first-24-week and continuation coverage phases, calendar-year ceiling buckets, and the checklist described in this guide.
English readers can use the worked formulas below to audit a hospital quote while treating the Korean insurer and hospital records as authoritative.
Where belimumab fits within lupus care
The 2023 EULAR recommendations place hydroxychloroquine at the foundation of SLE treatment unless it is contraindicated, with a target dose discussed in relation to actual body weight and individual retinal risk.
Glucocorticoids are generally used as bridging treatment for active inflammation while clinicians try to minimise long-term exposure.
Immunosuppressive medicines and biologic therapies may be added according to organ involvement, severity, prior response, safety, fertility plans, and other patient factors.
These clinical choices cannot be reduced to a cost-ranking table.
Why prior standard therapy matters
- Korean HIRA coverage for belimumab requires at least three months of standard therapy with corticosteroids, an antimalarial, or an immunosuppressant used alone or in combination
- A medication list should record the dose, dates, response, adverse effects, and reason for stopping rather than only the product name
- Routine budgets can also include blood and urine tests, complement and anti-dsDNA follow-up, eye monitoring, bone protection, vaccination, and infection evaluation
- The most reliable input is a recent Korean itemised receipt or a written hospital quote rather than an online average
What the belimumab model does
- Calculates the intravenous target dose at 10 mg/kg from current body weight
- Searches integer quantities of 120 mg and 400 mg vials for the lowest list-price combination that reaches the target
- Builds loading doses on days 0, 14, and 28 followed by doses every 28 days
- Separates HIRA-eligible doses from hypothetical full-self-pay doses after a failed continuation check
- Adds user-entered covered infusion services and non-covered spending without pretending to know a hospital’s final tariff
EULAR provides an international clinical framework, while HIRA decides the Korean reimbursement criteria used here.
A medicine may be clinically considered yet fail a particular reimbursement rule, and a reimbursement checklist can be met without making the medicine the right clinical choice for a specific person.
Keep those two questions separate during a consultation.
Official 2026 Benlysta vial prices used by the calculator
HIRA’s medicine price history lists a benefit-ceiling price effective January 1, 2026 of KRW 182,286 for the 120 mg vial and KRW 607,980 for the 400 mg vial.
The Korean product codes are 650002901 for 120 mg and 650002891 for 400 mg.
A benefit-ceiling price is a reimbursement-list input, not a promise that the final receipt will equal that number.
Consultation, infusion administration, laboratory work, supplies, and hospital billing details can add separate amounts.
South Korea 2026 Benlysta intravenous vial prices and product codes| Product | Product code | Strength | 2026 ceiling price |
|---|
| Benlysta intravenous vial | 650002901 | 120 mg | KRW 182,286 |
| Benlysta intravenous vial | 650002891 | 400 mg | KRW 607,980 |
How infusion dates are counted
The intravenous schedule starts with doses on day 0, day 14, and day 28, followed by one dose every 28 days.
The model adds the selected number of calendar months to the start date and includes doses strictly before that end date.
A twelve-month plan therefore usually contains 15 infusions, including a dose around day 364, rather than simply twelve monthly doses.
A one-month plan includes the three loading doses on days 0, 14, and 28.
HIRA initial reimbursement checklist
The coverage criteria were cross-checked against HIRA Notice 2025-129, effective August 1, 2025, and reviewed again on July 19, 2026.
For this SLE indication, the public checklist describes an adult with active, autoantibody-positive disease after at least three months of standard therapy.
The calculator marks initial eligibility only when every listed input is satisfied.
Required initial inputs
- Age 18 or older
- At least three months of standard therapy
- SELENA-SLEDAI 10 or higher
- Positive anti-dsDNA
- Low complement C3 or C4
- No severe active central nervous system SLE under this criterion
- No severe active lupus nephritis under this criterion
What a green checklist cannot prove
- Whether the medical record uses the required dates, tests, definitions, and documentation
- Whether an insurer review or hospital claim will approve the medicine
- Whether belimumab is clinically preferable to another treatment
- Whether an exclusion, contraindication, infection, pregnancy issue, or interaction changes the plan
- Whether the special-case registration applies to the same claim
The exact boundary matters.
Age 17 fails while age 18 meets the age field, two months of standard therapy fails while three months meets the duration field, and a SELENA-SLEDAI of 9 fails while 10 meets the score field.
Positive anti-dsDNA and low C3 or C4 are both required in the model.
Selecting severe active CNS disease or severe active nephritis makes this particular public SLE coverage check fail.
Week-24 response and continuation through 84 months
HIRA’s continuation rule requires the SELENA-SLEDAI score at week 24 to fall by at least 4 points from the initial assessment.
If that response is documented, reimbursement can be reviewed for another six months.
The same first-24-week response must then be maintained at each six-month review, and the public maximum covered duration is 84 months.
How the cost engine splits the timeline
- Doses through day 168 use the initial eligibility checklist
- Later doses require both the initial checklist and a week-24 decrease of at least 4 points
- Later doses also require the input confirming that the original response remains maintained
- If continuation inputs fail, later drug cost is shown as a hypothetical 100% self-pay amount
- The hypothetical self-pay line is a budget contrast, not advice to continue ineffective or non-reimbursed treatment
Exclusion does not mean no treatment is needed
Severe active CNS SLE and severe active lupus nephritis are excluded from this public belimumab SLE coverage criterion.
That does not mean the conditions are minor or should be left untreated.
They may demand urgent organ-specific assessment, a different treatment pathway, and coordinated rheumatology, nephrology, neurology, or inpatient care.
The KDIGO lupus nephritis guideline is a useful clinical reference, but it is not a substitute for the Korean claim criteria or the treating team’s judgment.
M32.1 and V136 special-case coverage is not automatic for every SLE diagnosis
South Korea’s current special-case rule is the Ministry of Health and Welfare Notice 2026-101, effective May 1, 2026.
Annex 4 lists systemic lupus erythematosus with organ or system involvement under M32.1, together with specified complications, under special code V136.
It does not turn every broad SLE label or every M32 code into automatic special-case coverage.
When the 10% scenario is useful
- The patient has confirmed V136 registration for the listed M32.1 condition or specified complication
- The registration period includes the treatment date
- The covered service is directly related to the registered rare disease
- The drug or service separately meets its own reimbursement criteria
- The receipt or hospital office confirms that the special code applies to the claim
When not to assume 10%
- The only information available is a broad SLE diagnosis without a V136 registration record
- The service happened before the effective registration date or after the registration expired
- The visit concerns an unrelated condition rather than the registered rare disease
- The item is non-covered or the medicine is used outside its reimbursement criteria
- The hospital bill uses a different copay treatment after reviewing the full claim
Registered rare-disease special-case care generally uses a 10% covered copay for five years under the current notice.
A patient who continues to need treatment may be eligible for re-registration after the requirements are checked.
An application filed within 30 days of confirmed diagnosis can apply from the confirmation date, while a later application generally applies from the filing date.
Those timing rules can explain why two receipts around registration show different copays.
Vial optimisation formula and worked examples
The target dose is body weight multiplied by 10 mg/kg.
The model then tests non-negative integer counts of the 120 mg and 400 mg vials until the prepared dose reaches or exceeds the target.
It chooses the lowest total price first, then the least waste if prices tie, and finally the fewest total vials if both price and waste tie.
Exact planning equations
Target dose in mg = body weight in kg × 10
Prepared mg = 120 × count of 120 mg vials + 400 × count of 400 mg vials
Prepared mg must be at least the target dose
Infusion drug price = KRW 182,286 × 120 mg count + KRW 607,980 × 400 mg count
Calculated waste in mg = prepared mg − target mg
Worked belimumab vial combinations by body weight using 2026 Korean prices| Weight | Target dose | Lowest-price vial mix | Prepared | Waste | One-infusion price |
|---|
| 60 kg | 600 mg | Five 120 mg vials | 600 mg | 0 mg | KRW 911,430 |
| 70 kg | 700 mg | Six 120 mg vials | 720 mg | 20 mg | KRW 1,093,716 |
| 80 kg | 800 mg | Two 400 mg vials | 800 mg | 0 mg | KRW 1,215,960 |
For a 60 kg example, the target is 600 mg and five 120 mg vials cost KRW 911,430 per infusion with no calculated waste.
Fifteen infusions over a typical twelve-month planning window produce a list drug cost of KRW 13,671,450.
If every dose meets reimbursement and V136 special-case coverage applies, a simple 10% drug-only copay is KRW 1,367,145 before any annual ceiling analysis.
At a 60% tertiary-outpatient ordinary rate, the same drug-only list produces KRW 8,202,870, while outside-criteria use is modelled at the full KRW 13,671,450.
None of those three figures includes infusion administration, visits, laboratory tests, other medicines, transport, accommodation, or lost work time.
How the calculator assembles the patient cost
Each selected treatment month creates one planning event for the monthly covered-care input and one for the monthly non-covered input.
Each belimumab date creates a drug event and adds the user-entered covered infusion-service amount.
Eligible drug events enter the covered-allowable bucket, while non-eligible drug events enter an outside-criteria full-self-pay bucket.
Events are grouped by their calendar year before the optional annual ceiling is applied.
Cost equations by calendar year
Covered rate = 10% if verified V136 applies, otherwise the selected 20% to 60% ordinary rate
Covered copay before ceiling = rounded covered allowable cost × covered rate
Covered copay after ceiling = lower of the covered copay and the selected 2026 income-tier ceiling
Ceiling refund estimate = covered copay before ceiling − covered copay after ceiling
Patient total = covered copay after ceiling + non-covered care + outside-criteria drug cost
Included in the simplified ceiling bucket
- The patient copay on reimbursement-eligible belimumab drug cost
- The patient copay on user-entered monthly covered lupus care
- The patient copay on user-entered covered infusion services
- Only costs occurring within the same calendar year bucket
Excluded from the simplified ceiling bucket
- Non-covered monthly spending
- Belimumab drug cost outside the public reimbursement criteria
- Medical spending not entered into the calculator
- Items that NHIS excludes under the detailed ceiling rules
- Private indemnity benefits, tax credits, and catastrophic-expense support
Ordinary copays and the annual out-of-pocket ceiling
National Health Insurance Act Article 44 establishes patient cost sharing and the annual out-of-pocket ceiling framework.
Enforcement Decree Article 19 and Annex 2 provide the ordinary patient shares used as simplified options here: 20% for inpatient care and 30%, 40%, 50%, or 60% for outpatient care by provider type.
The receipt and the detailed claim rule always control over a user-selected label.
Simplified Korean patient copay rates and 2026 annual ceiling assumptions| Setting or income tier | Planning rate or ceiling | Use in this model |
|---|
| Verified V136-related covered care | 10% | Overrides the selected ordinary rate for the scenario |
| Inpatient or outpatient by provider tier | 20% to 60% | Used only when special-case coverage is not selected |
| Income tiers 1 to 3 | KRW 900,000 to 1,120,000 | 2026 reference values applied separately per calendar year |
| Income tiers 4 to 7 | KRW 1,730,000 to 3,260,000 | Other medical spending is not automatically imported |
| Income tiers 8 to 10 | KRW 4,460,000 to 8,430,000 | Actual NHIS income-tier assignment and settlement prevail |
A plan beginning in July and running for twelve months crosses two calendar years.
The calculator therefore applies a separate ceiling to each partial-year bucket rather than treating the twelve-month treatment anniversary as one statutory year.
It holds the 2026 reference ceiling constant in later modelled years, so a long 84-month scenario must be updated when later annual figures are published.
Actual NHIS settlement also considers other covered care, detailed exclusions, claim completion dates, and the official income tier.
Step-by-step use for an auditable estimate
- Choose the treatment scenario.
Use standard care for receipt-based monthly spending only, or add intravenous belimumab for vial, schedule, and reimbursement modelling.
- Enter the actual start date and planning months.
The start date controls both infusion dates and the calendar year assigned to each cost event.
- Use a current measured body weight.
The model keeps one decimal place and limits the planning range to 20 through 250 kg, but the prescriber decides the clinically used weight and dose.
- Replace list prices only with a traceable quote.
Keep the HIRA defaults when no written hospital figure is available, and remember that administration charges remain separate.
- Copy reimbursement inputs from the clinical record.
Do not guess the SELENA-SLEDAI score, antibody result, complement status, exclusion status, or week-24 response to make the result turn green.
- Enter covered and non-covered costs separately.
A hospital estimate should distinguish the drug, infusion service, tests, visits, and non-covered items so the ceiling calculation does not absorb ineligible spending.
- Select V136 only after verification.
Check the registration code, effective dates, and relationship between the service and the registered M32.1 condition.
- Read the year-by-year table and warnings.
A low covered copay can coexist with a large non-covered or outside-criteria amount, so the final patient total is more informative than the percentage badge alone.
Questions to bring to the rheumatology and billing teams
Disease activity evidence
- The latest SELENA-SLEDAI score and assessment date
- Anti-dsDNA result, unit, and test date
- C3 and C4 values with the laboratory reference range
- Current organ involvement and recent admissions
Prior treatment evidence
- Medicine names, doses, start dates, and stop dates
- Whether standard therapy has reached three months
- Insufficient response, adverse effects, or contraindications
- Current glucocorticoid dose and taper plan
Coverage evidence
- V136 registration record and effective dates
- The KCD code expected on the claim
- The provider category and expected patient share
- Written drug, infusion, visit, and test estimates
Safety discussion
- Current infection symptoms and recent vaccinations
- Pregnancy plans, pregnancy, or breastfeeding
- Other immunosuppressive medicines and supplements
- New neurologic symptoms, swelling, urine change, or blood pressure change
A good cost conversation uses the same dates and categories as the medical record.
Ask whether the quote uses the 120 mg vial, the 400 mg vial, or both, whether it includes administration and laboratory work, and which items are non-covered.
Also ask when the week-24 response assessment must be documented and who will check the next six-month review date.
Clinical and financial limits of the estimate
Clinical limits
- No diagnosis or confirmation that symptoms are caused by SLE
- No prediction of organ damage, flare risk, response, or adverse effects
- No recommendation to start, continue, switch, or stop belimumab
- No dosing adjustment for a specific clinical circumstance
- No substitute for specialist management of CNS disease or lupus nephritis
Financial limits
- No guarantee that a hospital uses the mathematically cheapest vial combination
- No automatic knowledge of consultation, laboratory, administration, or supply tariffs
- No private indemnity insurance, medical-expense tax credit, or public assistance calculation
- No final HIRA prior review, claim adjudication, or NHIS ceiling settlement
- No automatic update of ceiling values for years after 2026 in a long scenario
Urgent symptoms come before cost planning
Sudden neurologic symptoms, confusion, severe headache, chest pain, breathing difficulty, high fever, rapidly increasing swelling, a major fall in urine output, or visible blood in urine needs prompt medical assessment.
A suspected infection during immunosuppressive treatment or a serious reaction after a new medicine also requires contact with the treating service rather than waiting for an online estimate.
Frequently asked questions
Does every Korean SLE patient automatically pay 10%?
No. The current rare-disease special-case annex specifically lists M32.1 with organ or system involvement and specified complications under V136. Confirm the registration code, dates, and relationship to the current covered service.
Is SELENA-SLEDAI 10 enough by itself for reimbursement?
No. The public checklist also includes age 18 or older, at least three months of standard therapy, positive anti-dsDNA, low C3 or C4, and the two severe active disease exclusions. The actual record and review determine coverage.
What happens in the model if the week-24 score falls by only 3 points?
Three points misses the public continuation boundary of 4 points. The model keeps the first-24-week eligible segment and places later drug events in a hypothetical full-self-pay segment. That display is not advice to continue treatment.
Why can five small vials cost less than a mixed vial combination?
The 2026 listed prices are not exactly proportional by milligram. The algorithm compares total price, not simply the fewest vials, and then uses waste and vial count as tie-breakers. Hospital preparation and billing may still differ.
Can this guide estimate subcutaneous Benlysta?
No. The detailed model is intentionally limited to the Korean intravenous 120 mg and 400 mg vial prices and the corresponding 10 mg/kg schedule verified for this release. Check the current MFDS, HIRA, supply, and price status for another formulation.
Is the displayed ceiling refund guaranteed?
No. It is a calendar-year planning estimate using only the covered spending entered here and 2026 reference ceiling values. NHIS uses the official income tier, completed claims, detailed exclusions, and other eligible spending.
Can a patient with lupus nephritis still use the calculator?
Standard-care spending can still be entered, but severe active lupus nephritis fails this particular public belimumab SLE checklist. Kidney disease needs organ-specific evaluation and may follow a separate clinical and reimbursement pathway.
Why does a twelve-month plan show 15 infusions?
The schedule uses day 0, day 14, day 28, and then every 28 days. A dose near day 364 can occur before the calendar anniversary, so a year is not the same as twelve once-monthly doses.
When should the prices and rules be checked again?
Check before starting treatment, after moving hospitals, when HIRA publishes a new price list or reimbursement notice, when the special-case annex changes, and when a new annual ceiling applies. The current values were verified on July 19, 2026.
Does the model decide whether belimumab is worth the cost?
No. It reports cost categories and public-rule checkpoints. Value depends on clinical goals, organ protection, prior treatment, safety, patient preferences, and alternatives assessed with the treating team.
Primary sources and verification date
The Korean prices, reimbursement criteria, special-case rule, and statutory framework were checked against official sources on July 19, 2026.
A later official notice, price history entry, or statute takes priority over this page.
Turn the estimate into a consultation checklist
Bring the weight, laboratory dates, SELENA-SLEDAI record, V136 registration details, and itemised hospital quote to the treating team.
The current rheumatology assessment, hospital billing office, NHIS, and HIRA decision always take priority over this planning result.